AN2 Therapeutics (ANTX) vs Tiziana Life Sciences (TLSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AN2 Therapeutics (ANTX) has outperformed Tiziana Life Sciences (TLSA) over the past year, gaining 254.8% versus a loss of 44.1%. AN2 Therapeutics is the larger company by market cap ($166.0 million vs $151.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANTX | TLSA |
|---|---|---|
| Share price | $4.40 | $1.19 |
| Market cap | $166.04M | $151.44M |
| 1-day change | -5.98% | +5.31% |
| YTD return | +285.96% | -20.13% |
| 1-year return | +254.84% | -44.13% |
| 5-year return | — | -21.19% |
| EPS (TTM) | $-1.05 | $-0.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.19 | $2.20 |
| 52-week low | $1.00 | $0.76 |
| Distance from 52-week high | -38.80% | -45.91% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +104.55% | +572.27% |
| Average volume | 237.87K | 754.20K |
| Shares outstanding | 37.74M | 127.26M |
| Employees | 21 | 10 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANTX has outperformed TLSA by 299.0 percentage points over the past year.
About AN2 Therapeutics
ANTX stock →AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 21 employees
About Tiziana Life Sciences
TLSA stock →Tiziana Life Sciences Ltd, together with its subsidiaries, engages in the research and development of therapies for neurodegenerative and neuroinflammatory diseases in the United Kingdom and internationally. It develops Foralumab TZLS-401, a human anti-CD3 monoclonal antibody, which is Phase II clinical trial for the treatment of non-active secondary progressive multiple sclerosis, Alzheimer's disease, multi system atrophy, and amyotrophic lateral sclerosis; and TZLS-501, a human anti-IL-6R monoclonal antibody for the treatment of autoimmune and inflammatory diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees
ANTX vs TLSA FAQ
Which is bigger, AN2 Therapeutics or Tiziana Life Sciences?
AN2 Therapeutics (ANTX) is larger, with a market capitalization of $166.04M compared with $151.44M for Tiziana Life Sciences (TLSA).
Which stock has performed better over the past year, ANTX or TLSA?
ANTX returned +254.84% over the past 12 months, compared with -44.13% for TLSA (price return, excluding dividends). Past performance does not predict future results.
Are AN2 Therapeutics and Tiziana Life Sciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.